The Side Effect Nobody Reported

Social media has become an important source of real-world patient safety information, yet many pharmacovigilance systems were designed around traditional reporting channels. Patients may discuss adverse reactions, quality-of-life impacts, treatment experiences and other safety-relevant information online without ever reporting them through conventional channels.

In this POV, Dr. Narayan Tripathi, Senior Director, Pharmacovigilance at EVERSANA, explores why social media monitoring deserves a more systematic place within modern pharmacovigilance and what companies can do to close the gap.

Why social media monitoring matters for pharmacovigilance

Traditional pharmacovigilance systems depend heavily on information that reaches the organization through established channels, including medical information, field teams and literature monitoring. Social media works differently: patients may post about their experiences in forums, comments and other public digital conversations without the company ever seeing them.

That creates three important considerations for life sciences organizations:

1. Adverse drug reactions remain underreported

The POV cites research estimating that roughly 94% of adverse drug reactions are never reported through spontaneous reporting systems. Social media provides another source of publicly available real-world safety information that may capture patient experiences not surfaced through traditional reporting channels.

2. Digital safety monitoring carries regulatory implications

The POV examines expectations established through GVP Module VI, ICH E2D and 21 CFR 314.80 surrounding safety information identified through internet and digital sources. It also highlights the importance of having defined monitoring processes, responsibilities, escalation pathways and audit trails.

3. Social media can reveal different patient experiences

Online conversations may surface quality-of-life events, sensitive experiences, real-world interactions and emerging observations that patients do not necessarily raise through conventional reporting channels. The POV argues that social media should complement, rather than replace, established spontaneous reporting.

What does effective social media pharmacovigilance look like?

Effective monitoring requires more than simply having a social listening platform.

In the full POV, Dr. Tripathi outlines six elements of a systematic approach, including defined monitored platforms, risk-based screening frequency, documented processes, trained validity assessment, clear escalation into the pharmacovigilance team and a complete audit trail.

He also explores how EVERSANA Orchestrate™ PV SimplifAI brings social media into the broader pharmacovigilance operation through AI-supported screening combined with human review and established safety workflows.

The story of your product’s safety will be told somewhere. The only question is whether you read it first.

Is your pharmacovigilance strategy capturing the patient conversations that matter?

Download The Side Effect Nobody Reported to explore the gaps in traditional social media safety monitoring, regulatory considerations and a practical framework for bringing digital conversations into a modern pharmacovigilance operation.

Download Now